Endurance Wealth Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $4.67M | Sell |
127,360
-701
| -0.5% | -$27.3K | 0.64% | 44 |
|
|
2023
Q1 | $5.22M | Buy |
128,061
+2,758
| +2% | +$119K | 0.74% | 38 |
|
|
2022
Q4 | $6.42M | Sell |
125,303
-150
| -0.1% | -$7.19K | 0.97% | 32 |
|
|
2022
Q3 | $5.49M | Buy |
125,453
+2,993
| +2% | +$145K | 0.91% | 31 |
|
|
2022
Q2 | $6.42M | Sell |
122,460
-279
| -0.2% | -$14.2K | 0.98% | 30 |
|
|
2022
Q1 | $6.36M | Sell |
122,739
-17,749
| -13% | -$921K | 0.82% | 35 |
|
|
2021
Q4 | $8.3M | Buy |
140,488
+474
| +0.3% | +$23.5K | 0.89% | 33 |
|
|
2021
Q3 | $6.02M | Sell |
140,014
-835
| -0.6% | -$37K | 0.67% | 43 |
|
|
2021
Q2 | $5.51M | Sell |
140,849
-352
| -0.2% | -$13.7K | 0.61% | 47 |
|
|
2021
Q1 | $5.12M | Sell |
141,201
-2,124
| -1% | -$75.4K | 0.6% | 46 |
|
|
2020
Q4 | $5.28M | Sell |
143,325
-6,086
| -4% | -$223K | 0.67% | 42 |
|
|
2020
Q3 | $5.2M | Buy |
149,411
+16,740
| +13% | +$587K | 0.77% | 36 |
|
|
2020
Q2 | $4.12M | Sell |
132,671
-27,004
| -17% | -$917K | 0.68% | 44 |
|
|
2020
Q1 | $4.94M | Hold |
159,675
| – | – | 0.95% | 33 |
|
|
2019
Q4 | $5.93M | Sell |
159,675
-305
| -0.2% | -$10.9K | 0.91% | 32 |
|
|
2019
Q3 | $5.45M | Sell |
159,980
-3,979
| -2% | -$145K | 0.91% | 33 |
|
|
2019
Q2 | $6.74M | Sell |
163,959
-15,714
| -9% | -$624K | 1.06% | 29 |
|
|
2019
Q1 | $7.24M | Sell |
179,673
-504
| -0.3% | -$20.2K | 1.19% | 26 |
|
|
2018
Q4 | $7.46M | Sell |
180,177
-2,321
| -1% | -$96.3K | 1.39% | 23 |
|
|
2018
Q3 | $7.63M | Sell |
182,498
-2,187
| -1% | -$84.2K | 1.2% | 27 |
|
|
2018
Q2 | $6.36M | Sell |
184,685
-3,594
| -2% | -$123K | 1.05% | 28 |
|
|
2018
Q1 | $6.34M | Sell |
188,279
-4,926
| -3% | -$169K | 1.07% | 27 |
|
|
2017
Q4 | $6.64M | Sell |
193,205
-7,274
| -4% | -$248K | 1.07% | 26 |
|
|
2017
Q3 | $6.79M | Sell |
200,479
-4,899
| -2% | -$157K | 1.13% | 28 |
|
|
2017
Q2 | $6.55M | Sell |
205,378
-79
| -0% | -$2.49K | 1.11% | 29 |
|
|
2017
Q1 | $6.67M | Sell |
205,457
-1,640
| -0.8% | -$51.7K | 1.15% | 31 |
|
|
2016
Q4 | $6.38M | Sell |
207,097
-7,009
| -3% | -$214K | 1.14% | 30 |
|
|
2016
Q3 | $6.83M | Buy |
214,106
+4,452
| +2% | +$149K | 1.22% | 28 |
|
|
2016
Q2 | $7M | Buy |
209,654
+4,929
| +2% | +$157K | 1.32% | 27 |
|
|
2016
Q1 | $5.76K | Sell |
204,725
-12,113
| -6% | -$346K | 0.81% | 32 |
|
|
2015
Q4 | $6.64M | Sell |
216,838
-4,622
| -2% | -$145K | 1.26% | 29 |
|
|
2015
Q3 | $6.98M | Sell |
221,460
-10,773
| -5% | -$345K | 1.23% | 23 |
|
|
2015
Q2 | $7.39M | Sell |
232,233
-44,478
| -16% | -$1.45M | 1.24% | 23 |
|
|
2015
Q1 | $9.13M | Sell |
276,711
-55,108
| -17% | -$1.75M | 1.59% | 14 |
|
|
2014
Q4 | $9.81M | Sell |
331,819
-3,054
| -0.9% | -$87.6K | 1.76% | 12 |
|
|
2014
Q3 | $9.39M | Sell |
334,873
-6,087
| -2% | -$171K | 1.75% | 11 |
|
|
2014
Q2 | $9.6M | Sell |
340,960
-9,725
| -3% | -$277K | 1.6% | 13 |
|
|
2014
Q1 | $10.7M | Sell |
350,685
-3,193
| -0.9% | -$95.2K | 2.07% | 8 |
|
|
2013
Q4 | $10.3M | Buy |
353,878
+4,848
| +1% | +$141K | 2.03% | 8 |
|
|
2013
Q3 | $9.51M | Buy |
349,030
+2,899
| +0.8% | +$78.9K | 2.01% | 10 |
|
|
2013
Q2 | $9.2M | Buy |
+346,131
| New | +$9.56M | 2.06% | 8 |
|
Other funds holding PFE
Endurance Wealth Management's PFE Position: Q2 2023 in Review
Endurance Wealth Management reduced its Pfizer (PFE) stake by 0.55% in Q2 2023, selling an estimated $27.3K and leaving 127,360 shares worth $4.67M. The position accounts for 0.64% of the portfolio, ranked #44.
Endurance Wealth Management first reported a position in PFE in Q2 2013 and has held it in 41 quarters since. The position peaked at $10.7M in Q1 2014. 3,042 funds tracked by Wall St. Rank hold PFE as of Q2 2023.
- Endurance Wealth Management held 127,360 shares of Pfizer worth $4.67M as of Q2 2023.
- Endurance Wealth Management sold 701 Pfizer shares in Q2 2023, an estimated $27.3K.
- Pfizer made up 0.64% of Endurance Wealth Management's portfolio in Q2 2023, its #44 holding.
- Endurance Wealth Management first reported a position in Pfizer in Q2 2013 and has held it in 41 quarters since.
- Endurance Wealth Management's Pfizer position peaked at $10.7M in Q1 2014.
- 3,042 funds tracked by Wall St. Rank held Pfizer as of Q2 2023.
Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.